IRIS
TOSCA, ELENA MARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.764
AS - Asia 1.260
EU - Europa 961
SA - Sud America 307
AF - Africa 50
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 2
Totale 4.352
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.714
CN - Cina 418
SG - Singapore 322
IT - Italia 244
BR - Brasile 227
VN - Vietnam 211
IE - Irlanda 186
RU - Federazione Russa 162
HK - Hong Kong 131
DE - Germania 86
FR - Francia 74
FI - Finlandia 41
GB - Regno Unito 41
IN - India 36
ZA - Sudafrica 31
AR - Argentina 27
MX - Messico 22
JP - Giappone 20
SE - Svezia 20
NL - Olanda 18
ES - Italia 17
CA - Canada 16
PL - Polonia 16
CO - Colombia 15
IQ - Iraq 15
BD - Bangladesh 14
AT - Austria 11
EC - Ecuador 11
IR - Iran 10
CL - Cile 9
ID - Indonesia 9
TR - Turchia 9
BE - Belgio 8
CZ - Repubblica Ceca 8
MY - Malesia 8
VE - Venezuela 7
AU - Australia 6
DO - Repubblica Dominicana 6
PK - Pakistan 6
SA - Arabia Saudita 6
JO - Giordania 5
UA - Ucraina 5
AE - Emirati Arabi Uniti 4
ET - Etiopia 4
LT - Lituania 4
PH - Filippine 4
PS - Palestinian Territory 4
UZ - Uzbekistan 4
AL - Albania 3
CH - Svizzera 3
KE - Kenya 3
LK - Sri Lanka 3
PE - Perù 3
TN - Tunisia 3
TW - Taiwan 3
UY - Uruguay 3
AZ - Azerbaigian 2
BO - Bolivia 2
CR - Costa Rica 2
HU - Ungheria 2
IL - Israele 2
KR - Corea 2
KZ - Kazakistan 2
LB - Libano 2
LV - Lettonia 2
MA - Marocco 2
NZ - Nuova Zelanda 2
PY - Paraguay 2
QA - Qatar 2
RO - Romania 2
SI - Slovenia 2
BB - Barbados 1
BG - Bulgaria 1
BH - Bahrain 1
BY - Bielorussia 1
DM - Dominica 1
DZ - Algeria 1
EG - Egitto 1
EU - Europa 1
GE - Georgia 1
GR - Grecia 1
GT - Guatemala 1
GW - Guinea-Bissau 1
GY - Guiana 1
HR - Croazia 1
LA - Repubblica Popolare Democratica del Laos 1
LC - Santa Lucia 1
LU - Lussemburgo 1
MN - Mongolia 1
MU - Mauritius 1
NG - Nigeria 1
NO - Norvegia 1
NP - Nepal 1
OM - Oman 1
SN - Senegal 1
UG - Uganda 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 4.352
Salva come PNG Salva come JPEG
Città #
Dallas 297
Dublin 186
Ashburn 185
Singapore 166
San Jose 162
Chandler 148
Hong Kong 124
Beijing 113
Ho Chi Minh City 92
Pavia 72
Los Angeles 71
Boardman 69
Lauterbourg 47
New York 46
Hanoi 43
Shanghai 41
Moscow 38
Munich 36
Nanjing 32
Redondo Beach 32
Johannesburg 31
São Paulo 28
Council Bluffs 26
Lawrence 26
Medford 26
Milan 26
Princeton 26
Buffalo 25
Helsinki 20
Wilmington 20
Turku 18
Dearborn 17
Jacksonville 17
Shenyang 17
Hebei 15
Nanchang 15
Orem 15
Warsaw 15
Florence 14
Tokyo 14
Santa Clara 13
Brooklyn 12
Atlanta 10
Da Nang 10
Guangzhou 10
Rome 10
Stockholm 10
Tianjin 10
Changsha 9
Frankfurt am Main 9
Nuremberg 9
Ann Arbor 8
Chennai 8
Denver 8
Jiaxing 8
Mexico City 8
Montreal 8
Paris 8
Rio de Janeiro 8
Brussels 7
Chicago 7
Eindhoven 7
Houston 7
London 7
Poplar 7
Washington 7
Brescia 6
Düsseldorf 6
Hyderabad 6
Medellín 6
Mira 6
Porto Alegre 6
San Francisco 6
Boston 5
Bắc Ninh 5
Fortaleza 5
Girifalco 5
Heemskerk 5
Kunming 5
Pittsburgh 5
Seattle 5
Tehran 5
Addis Ababa 4
Amsterdam 4
Ankara 4
Baghdad 4
Biên Hòa 4
Bogotá 4
Brasília 4
Bắc Giang 4
Cagliari 4
Can Tho 4
Caracas 4
Castano Primo 4
Dhaka 4
Fairfield 4
Falkenstein 4
Genoa 4
Guayaquil 4
Haiphong 4
Totale 2.795
Salva come PNG Salva come JPEG
Nome #
Quantitative evaluation of RC-106 antitumor activity in GBM spheroids through tumor growth inhibition modeling based on cell counts data 173
Methods and tools for multiscale modelling in Systems Pharmacology: a review 128
Dynamic energy budget based models of tumor-in-host growth inhibition and cachexia onset in preclinical settings. 120
Artificial intelligence and machine learning: just a hype or a new opportunity for pharmacometrics? 117
Leveraging Two-Stage delta Global Sensitivity Analysis method to inform parameter estimation in PBPK models 114
Evaluation of software tools for Bayesian estimation on population models:an update based on current software versions 114
A PK/PD model for tumor-in-host growth kinetics following administration of an antiangiogenic agent given alone or in combination regimens 112
Translating Preclinical Insights into Clinical Outcomes: A Predictive Framework for Overall response rate and time to progression in Solid Tumors 102
An integrated pipeline for evaluating antitumor efficacy of RC-106 on glioblastoma spheroids 102
Modeling tumor growth inhibition and toxicity outcome after administration of anticancer agents in xenograft mice: A Dynamic Energy Budget (DEB) approach 102
Cancer Cachexia: A Dynamic Energy Budget ({DEB})-Based Model for Tumor-Related Anorexia and Sarcopenia 99
Dealing with stochasticity in precision dosing decision-making processes by fully exploiting PK-PD modelling in Reinforcement Learning algorithms. A practical case-study on Vancomycin continuous infusion in ICU patients 96
A Dynamic Energy Budget (DEB) based modeling framework to describe tumor-in-host growth inhibition and cachexia onset during anticancer treatment in in vivo xenograft studies 96
Evaluation of a PK/PD DEB-based model for tumor-in-host growth kinetics under anticancer treatment 92
In vitro– in vivo correlation (Ivivc) population modeling for the in silico bioequivalence of a long‐acting release formulation of progesterone 91
Application of Artificial Neural Networks to Predict the Intrinsic Solubility of Drug-Like Molecules 91
A Population Dynamic Energy Budget-Based Tumor Growth Inhibition Model for Etoposide Effects on Wistar Rats 90
A genetic algorithm for covariate selection 90
Model-based analysis of patient-derived organoids for evaluating anticancer drugs 89
In vitro-in vivo correlation (IVIVC) population modeling for the in silico bioequivalence of a long-acting release formulation of Progesterone 87
A translational model-based approach to inform the choice of the dose in phase 1 oncology trials: the case study of erdafitinib 85
Development of a genetic algorithm for covariate analysis in population pharmacokinetic models 85
Combining Reinforcement Learning and PK-PD models to personalize multiple drug administration: an application to Axitinib-Anti-Hypertensive treatment in metastatic renal cancer patients 84
Facing the limits of the genetic algorithms for covariate selection 84
Evaluation of a tumor growth inhibition (TGI) model integrating dynamic energy budget (DEB) theory 83
Modeling approaches for reducing safety-related attrition in drug discovery and development: a review on myelotoxicity, immunotoxicity, cardiovascular toxicity, and liver toxicity 83
Dynamic Energy Budget (DEB) based models of tumor-in-host growth inhibition and cachexia onset 81
A tumor-in-host DEB-based approach for modeling cachexia and bevacizumab resistance 81
Modeling tumor growth inhibition in Glioblastoma spheroids after exposure to RC-106, a novel sigma receptors modulator 77
A Two-Stages Global Sensitivity Analysis by using the delta sensitivity index in presence of correlated inputs: Application on a Tumor Growth Inhibition model based on the Dynamic Energy Budget theory 75
A tumor-in-host Dynamic Energy Budget (DEB)-based paradigm for preclinical to clinical translation: predictions of tumor-in-host growth dynamics 75
Predicting tumor volume doubling time and progression-free survival curves in cancer patients from patient-derived-xenograft (PDX) models: a translational model-based population approach 71
Modeling resistance development to Bevacizumab in xenograft experiments by coupling hypoxia-mediated mechanism and a Dynamic Energy Budget (DEB) based tumor-in-host model 70
Integrating Reinforcement Learning and PK-PD modelling to enable precision dosing: a multi-objective optimization for the treatment of Polycithemia Vera patients with Givinostat 69
How Modelling and Simulations combined with Artificial Intelligence can improve Precision Dosing 69
Precision dosing by integrating Reinforcement Learning and PK-PD models: application to givinostat treatment of Polycythemia Vera 69
mvLognCorrEst: an R package for sampling from multivariate lognormal distributions and estimating correlations from uncomplete correlation matrix 66
Reduced food-intake and sarcopenia in animal models of cancer anorexia-cachexia syndrome: a Dynamic Energy Budget (DEB)-based modeling approach 66
A Two-Stages Global Sensitivity Analysis in presence of correlated inputs: Application on a Tumor-in-host-growth Inhibition model based on the Dynamic Energy Budget theory 65
PopPK-PD modelling of Carboplatin-induced myelosuppression to support therapeutic drug monitoring and dose individualization in cancer patients using Electronic Health Record Data 65
PKPD modelling of MEN1611 anti-tumor effect in xenograft models to predict efficacy threshold concentrations in HER2-positive advanced or metastatic breast cancer patient population 63
In silico trial for the assessment of givinostat dose adjustment rules based on the management of key hematological parameters in polycythemia vera patients 62
Predicting tumor dynamics in treated patients from patient-derived-xenograft mouse models: a translational model-based approach 61
Replacement, Reduction, and Refinement of Animal Experiments in Anticancer Drug Development: The Contribution of 3D In Vitro Cancer Models in the Drug Efficacy Assessment 59
Predicting ADMET properties from molecule SMILE: a bottom-up approach using attention-based Graph Neural Networks 58
Model-informed reinforcement learning for enabling precision dosing via adaptive dosing 58
Precision Dosing in Presence of Multiobjective Therapies by Integrating Reinforcement Learning and PK-PD Models: Application to Givinostat Treatment of Polycythemia Vera 57
A clinical trial simulator to predict the effect of an adaptive dosing regimen of an investigated compound on platelets, white blood cells and haematocrit in patients with Polycythemia Vera 57
Go beyond the limits of genetic algorithm in daily covariate selection practice 56
Staggered Herringbone Microfluid Device for the Manufacturing of Chitosan/TPP Nanoparticles: Systematic Optimization and Preliminary Biological Evaluation 56
Translational modeling of tumor response to treatment: bridging preclinical to clinical studies 55
Model-based prediction of effective target exposure for MEN1611 in combination with trastuzumab in HER2-positive advanced or metastatic breast cancer patients 52
Reinforcement Learning and PK-PD Models Integration to Personalize the Adaptive Dosing Protocol of Erdafitinib in Patients with Metastatic Urothelial Carcinoma 45
Predicting Tumor Volume Doubling Time and Progression-Free Survival in Untreated Patients from Patient-Derived-Xenograft (PDX) Models: A Translational Model-Based Approach 43
Modeling restoration of gefitinib efficacy by co-administration of MET inhibitors in an EGFR inhibitor-resistant NSCLC xenograft model: A tumor-in-host DEB-based approach 38
Impact of sampling procedure on individual pharmacokinetic parameter estimation methods 34
Totale 4.462
Salva come PNG Salva come JPEG
Categoria #
all - tutte 16.417
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.417
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20217 0 0 0 0 0 0 0 0 0 5 1 1
2021/2022151 2 2 10 0 4 4 7 27 10 5 18 62
2022/2023440 48 41 6 27 25 36 2 30 199 1 9 16
2023/2024303 27 62 15 14 25 54 18 20 6 16 8 38
2024/2025901 18 97 35 35 43 11 43 44 220 49 103 203
2025/20262.412 191 252 344 410 340 78 340 103 217 137 0 0
Totale 4.462